• 1
    Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S4756.
  • 2
    Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 35962.
  • 3
    Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int 2011; 31(Suppl 1): 6877.
  • 4
    Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 34355.
  • 5
    Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4: 4637.
  • 6
    Asselah T, Bièche I, Sabbagh A, et al. Gene expression and hepatitis C virus infection. Gut 2009; 58: 84658.
  • 7
    Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 51624.
  • 8
    Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 1869.
  • 9
    Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127: 134755.
  • 10
    Asselah T, Marcellin P. BILN 2061: a major step toward new therapeutic strategies in hepatitis C. J Hepatol 2004; 41: 17881.
  • 11
    McCown MF, Rajyaguru S, Kular S, et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53: 212932.
  • 12
    Zhou Y, Muh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282: 2261928.
  • 13
    Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007; 7: 130229.
  • 14
    Holler TP, Parkinson T, Pryde DC. Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. Expert Opin Drug Discov 2009; 4: 3.
  • 15
    Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96100.
  • 16
    Asselah T. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. J Hepatol 2011; 54: 106972.
  • 17
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 18
    Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 101424.
  • 19
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 241728.
  • 20
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 21
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 120717.
  • 22
    Asselah T. A sprint to increase response to HCV treatment: expectancies but caution. J Hepatol 2011; 55: 11548.
  • 23
    Asselah T. Realize the advance in HCV treatment, but remain cautious. J Hepatol 2011; 55: 145760.
  • 24
    Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 45968.
  • 25
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 58093.
  • 26
    Martinot-Peignoux M, Maylin S, Moucari R, et al. Virologic response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 2009; 14: 50111.
  • 27
    Susser S, Welch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 170918.
  • 28
    Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 70516.
  • 29
    Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131: 10408.
  • 30
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 391401.
  • 31
    Asselah T. Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. J Hepatol 2010; 52: 4524.
  • 32
    Dieterich D, Asselah T, Guyader D, et al. SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naïve patients with chronic genotype-1 HCV infection. Hepatology 2011; AASLD, A36.
  • 33
    Sulkowski MS, Asselah T, Ferenci P, et al. J. Treatment with the second generation HCV protease inhibitor BI201335 results in high and consistent SVR rates – results from SILEN-C1 in treatment-naïve patients across different baseline factors. Hepatology 2011; AASLD, A249.
  • 34
    Fried M, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment naive HCV genotype 1 patients: final analysis of the Pillar phase IIB study. Hepatology 2011; AASLD, LB-5.
  • 35
    Lawitz E, Rodriguez-Torres M, Stoehr E, et al. A Phase 2b study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. Hepatology 2011; AASLD, LB-13.
  • 36
    Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol 2011; 55: 9729.
  • 37
    Terrault N, Cooper C, Balart LA, et al. High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus PegIFN α-2a (40KD) and ribavirin (P/R) in treatment-naive HCV genotype 1 (G1) patients: results from the ATLAS study. Hepatology 2011; AASLD, A79.
  • 38
    Lawitz E, Lalezari JP, Hassanein T, et al. Once-daily PSI-7977 plus peg/RBV in treatment-naïve patients with HCV GT1: robust end of treatment response rates are sustained post-treatment. Hepatology 2011; AASLD, A225.
  • 39
    Gane EJ, Rodriguez-Torres M, Nelson DR, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. Hepatology 2008; 48: ALB10.
  • 40
    Lazelari J, Poordad F, Mehra P, et al. Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment-naive HCV genotype 1-infected subjects EASL 45th Annual Meeting April 14–18, 2010. J Hepatol 2010; 52: LB13.
  • 41
    Hammond JL, Purohit VS, Fang J, et al. Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor PF- 00868554 following multiple dose administration in healthy volunteers. Hepatology 2008; 48: 1898.
  • 42
    Wagner F, Thompson R, Kantaridis C, et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology 2011; 54: 509.
  • 43
    Lok AS, Gardiner DF, Lawitz E, et al.Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Hepatology 52, AASLD 2010; Abstract LB-8.
  • 44
    Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52: 82232.
  • 45
    Gane E, Roberts S, Stedman C, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 146775.
  • 46
    Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 204755.
  • 47
    Zeuzem S, Soriano V, Asselah T, et al. Virologic response to an interferon-free regimen of BI201335 and BI207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the SOUND-C2 study. Hepatology 2011; AASLD, LB-15.
  • 48
    Zeuzem S, Asselah T, Angus PW, et al., High sustained virologic response following interferon-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI201335, polymerase inhibitor BI207127 and ribavirin, followed by BI201335 and PegIFN/ribavirin – the SOUND-C1 study. Hepatology 2011; AASLD, A249.
  • 49
    Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C. Hepatology 2011; in press.
  • 50
    Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks; results in 100% SVR12 in HCV genotype 1 null responders. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011). Berlin. March 30–April 3. Abstract 418.
  • 51
    Nelson R, Gane EJ, Jacobson IM, et al. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. D. Hepatology 2011; AASLD, LB-14.